RT Journal Article
SR Electronic
T1 A Matter of Controversy: Is Radioiodine Therapy Favorable in Differentiated Thyroid Carcinoma?
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1195
OP 1201
DO 10.2967/jnumed.117.191338
VO 59
IS 8
A1 Matthias Schmidt
A1 Rainer Görges
A1 Alexander Drzezga
A1 Markus Dietlein
YR 2018
UL http://jnm.snmjournals.org/content/59/8/1195.abstract
AB Radioiodine therapy is a matter of controversy because different opinions exist about its use for differentiated thyroid carcinoma. The following article sheds light on the different opinions and explains why we advocate the use of radioiodine therapy in more than only high-risk patients. In comparison to other malignancies, differentiated thyroid carcinoma has a different tumor biology due to its usually slow growth pattern. Radioiodine therapy was first used about 75 y ago and provided cure at a time when prospective randomized controlled trials had yet to be developed. Large patient cohorts and usually at least a decade of clinical follow-up are needed to demonstrate a benefit from radioiodine therapy. Thus, especially in low-risk patients, many factors define an individual treatment decision, including tumor stage, extent of surgery, tumor biology, clinical and imaging data, life expectancy, and patient preferences.